Selected Grants
A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1
Clinical TrialPrincipal Investigator · Awarded by Servier Bio-Innovation, LLC · 2024 - 2029Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2023 - 2029Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2023 - 2029PTC596-LMS
Clinical TrialPrincipal Investigator · Awarded by PTC Therapeutics, Inc · 2022 - 2027PEAK
ResearchPrincipal Investigator · Awarded by Cogent Biosciences, Inc · 2022 - 2026A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1
Clinical TrialPrincipal Investigator · Awarded by Servier Bio-Innovation, LLC · 2024 - 2029Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2023 - 2029Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2023 - 2029PTC596-LMS
Clinical TrialPrincipal Investigator · Awarded by PTC Therapeutics, Inc · 2022 - 2027PEAK
ResearchPrincipal Investigator · Awarded by Cogent Biosciences, Inc · 2022 - 2026A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Clinical TrialPrincipal Investigator · Awarded by Inhibrx, Inc · 2022 - 2026Phase 3 Randomized Double-Blind Study of Abemaciclib versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Clinical TrialPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2022 - 2026ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB, AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB, IN PATIENTS WITH ADVANCED OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA OR MYXOFIBROSARCOMA WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Clinical TrialPrincipal Investigator · Awarded by Tracon Pharmaceuticals, Inc. · 2020 - 2025SARC032
Clinical TrialPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2017 - 2025A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by BioAtla, Inc · 2021 - 2024Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2020 - 2024Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2020 - 2024A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Clinical TrialPrincipal Investigator · Awarded by SpringWorks Therapeutics · 2019 - 2024A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Clinical TrialPrincipal Investigator · Awarded by Deciphera Pharmaceuticals, LLC · 2019 - 2024A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Clinical TrialPrincipal Investigator · Awarded by Ayala Pharmaceuticals, Inc · 2021 - 2024YH001/KN035SAR101/1004
Clinical TrialPrincipal Investigator · Awarded by Tracon Pharmaceuticals, Inc. · 2022 - 2024Trillium TTI-621-03
Clinical TrialPrincipal Investigator · Awarded by PF Argentum IP Holdings LLC · 2022 - 2023A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma
Clinical TrialPrincipal Investigator · Awarded by Rain Therapeutics, Inc. · 2022 - 2023A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma (CL-PTL-130)
Clinical TrialInvestigator · Awarded by Gradalis, Inc. · 2019 - 2023A Phase 1/2 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2021 - 2023Vimseltinib (DCC-3014) MOTION
Clinical TrialPrincipal Investigator · Awarded by Deciphera Pharmaceuticals, LLC · 2022 - 2023A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma""
Clinical TrialPrincipal Investigator · Awarded by NanoCarrier Co., Ltd. · 2017 - 2022A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma
Clinical TrialPrincipal Investigator · Awarded by Oncternal Therapeutics, Inc. · 2018 - 2022An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Clinical TrialPrincipal Investigator · Awarded by Blueprint Medicines Corporation · 2018 - 2022STARTRK-2
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2017 - 2022A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2016 - 2022"A Phase 3, Global, Randomized, Double-Blind Trial of Tazemetostat in Combination with Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma"
Clinical TrialPrincipal Investigator · Awarded by Epizyme, Inc · 2020 - 2022A Phase 2 Multi-Center Investigation of Efficacy of ABI-009 (nab-rapamycin) in Patients with Advanced Malignant Perivascular Epithelioid Tumors (PEComa)
Clinical TrialPrincipal Investigator · Awarded by AADi LLC · 2015 - 2021A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study of Orally administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Clinical TrialPrincipal Investigator · Awarded by Daiichi Pharmaceutical Corporation · 2015 - 2021A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas
Clinical TrialPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2014 - 2021A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Clinical TrialPrincipal Investigator · Awarded by Immune Design Corp. · 2016 - 2021A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene
ResearchPrincipal Investigator · Awarded by Arog Pharmaceuticals, Inc. · 2017 - 2020A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
Clinical TrialPrincipal Investigator · Awarded by Eli Lilly and Company · 2015 - 2020A Phase IB Dose-Escalation Study of TRC105 in combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma
Clinical TrialPrincipal Investigator · Awarded by Tracon Pharmaceuticals, Inc. · 2013 - 2020A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of MB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Following First-line Systemic Anti-cancer Therapy
Clinical TrialPrincipal Investigator · Awarded by Immune Design Corp. · 2018 - 2020SARC028: A phase II study of anti-PD1 antibody Pembrolizumab (MK-3475) in patients with advanced sarcomas
Clinical TrialPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2015 - 2020SARC 024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas - Cohort A
ResearchPrincipal Investigator · Awarded by Sarcoma Alliance for Research Through Collaboration · 2015 - 2018Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics
ResearchInvestigator · Awarded by National Institutes of Health · 2008 - 2013External Relationships
- Adaptimmune Therapeutics Plc
- Boehringer Ingelheim
- Daiichi Sankyo Co., Ltd
- Deciphera
- Springworks
- Adaptimmune Therapeutics Plc
- Boehringer Ingelheim
- Daiichi Sankyo Co., Ltd
- Deciphera
- Springworks
- WCG IRB
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.